Present Status and Current Treatment of the Patients Who Were Recruited and Randomized for the Study
| . | IFN-α . | Chemotherapy . |
|---|---|---|
| Total | 218 | 104 |
| Allogeneic BMT in chronic phase | 30 | 8 |
| Remaining | 188 | 96 |
| Alive, chronic phase | 52/188 (28%) | 14/96 (14%) |
| Alive, accelerated or blastic phase | 4/188 (2%) | 3/96 (3%) |
| Alive, total | 56/188 (30%) | 17/96 (18%) |
| Cytogenetic status (response) | ||
| Complete (Ph neg 100%) | 9/56 (16%) | 0/17 |
| Major (Ph neg 66% to 99%) | 7/56 (12%) | 0/17 |
| Minor (Ph neg 33% to 65%) | 4/56 (7%) | 1/17 (6%) |
| Minimal or none (Ph neg <33%) | 31/56 (55%) | 10/17 (59%) |
| Nonevaluable or unknown | 5/56 (9%) | 6/17 (35%) |
| Current treatment | ||
| IFN-α alone | 28/56 (50%) | 2/17 (12%) |
| IFN-α and chemotherapy | 10/56 (18%) | 1/17 (6%) |
| Chemotherapy | 16/56 (28%) | 14/17 (82%) |
| Unknown | 2/56 (4%) | 0/17 |
| . | IFN-α . | Chemotherapy . |
|---|---|---|
| Total | 218 | 104 |
| Allogeneic BMT in chronic phase | 30 | 8 |
| Remaining | 188 | 96 |
| Alive, chronic phase | 52/188 (28%) | 14/96 (14%) |
| Alive, accelerated or blastic phase | 4/188 (2%) | 3/96 (3%) |
| Alive, total | 56/188 (30%) | 17/96 (18%) |
| Cytogenetic status (response) | ||
| Complete (Ph neg 100%) | 9/56 (16%) | 0/17 |
| Major (Ph neg 66% to 99%) | 7/56 (12%) | 0/17 |
| Minor (Ph neg 33% to 65%) | 4/56 (7%) | 1/17 (6%) |
| Minimal or none (Ph neg <33%) | 31/56 (55%) | 10/17 (59%) |
| Nonevaluable or unknown | 5/56 (9%) | 6/17 (35%) |
| Current treatment | ||
| IFN-α alone | 28/56 (50%) | 2/17 (12%) |
| IFN-α and chemotherapy | 10/56 (18%) | 1/17 (6%) |
| Chemotherapy | 16/56 (28%) | 14/17 (82%) |
| Unknown | 2/56 (4%) | 0/17 |